StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.39−0.01 (-2.74%)

Close on Nov 20, 2026Market cap $94.94MP/E –Yield –

Outlook Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Outlook Therapeutics's free cash flow for the twelve months ending Sep 30, 2019 was -$32.73M. For fiscal 2019 it was -$32.73M. The highest annual figure on record is -$15.80M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2019Sep 30, 2019-$32.73M–
FY2018Sep 30, 2018-$35.82M–
FY2017Sep 30, 2017-$15.80M–
FY2016Sep 30, 2016-$46.58M–
FY2015Sep 30, 2015-$36.28M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2019CQ3 2019Sep 30, 2019-$5.94M–
Q3 FY2019CQ2 2019Jun 30, 2019-$10.46M–
Q2 FY2019CQ1 2019Mar 31, 2019-$6.31M–
Q1 FY2019CQ4 2018Dec 31, 2018-$10.02M–
Q4 FY2018CQ3 2018Sep 30, 2018-$9.66M-17383.5%
Q3 FY2018CQ2 2018Jun 30, 2018-$8.70M–
Q2 FY2018CQ1 2018Mar 31, 2018-$7.71M–
Q1 FY2018CQ4 2017Dec 31, 2017-$9.75M–
Q4 FY2017CQ3 2017Sep 30, 2017$55.87K–
Q3 FY2017CQ2 2017Jun 30, 2017-$5.71M–
Q2 FY2017CQ1 2017Mar 31, 2017-$4.15M–
Q1 FY2017CQ4 2016Dec 31, 2016-$5.99M–
Q4 FY2016CQ3 2016Sep 30, 2016-$10.70M–
Q3 FY2016CQ2 2016Jun 30, 2016-$16.49M–
Q2 FY2016CQ1 2016Mar 31, 2016-$7.01M–

More Outlook Therapeutics figures

See a number that looks wrong?